Conjugates comprising nanoparticles coated with platinum containing compounds

Patent metadata

Field	Value
Publication number	US-9023370-B2
Application number	US-200913140347-A
Country	US
Kind code	B2
Filing date	Dec 15, 2009
Priority date	Dec 16, 2008
Publication date	May 5, 2015
Grant date	May 5, 2015

Abstract

The present invention relates to conjugates of formula (I) having colloidal stability in a medium, wherein NP is a gold, silver or platinum nanoparticle; L is a linker selected from the group consisting of formula (II), formula (III), and a stereoisomer of any of the formulas (II) and (III), which is attached to the nanoparticle NP through sulfur atoms; wherein the meanings of X, n, p, Y and s are further specified in the description; and A is a platinum (II) biradical selected from the group consisting of formula (IV), formula (V) and formula (VI) including any of the stereoisomers of all of them, wherein the biradical is optionally in the form of a salt and is attached to the linker L through the single bonded oxygen atoms of the carboxyl groups. It also relates to a process for the preparation of the conjugates of formula (I) and to pharmaceutical compositions containing them. The conjugates of the invention are used for the treatment of cancer.

First claim

The invention claimed is:

1. A conjugate of the formula (I)
NP-L-A  (I)

having colloidal stability in a medium wherein
NP is a gold, silver or platinum nanoparticle;
L is a linker of formula (II) or a stereoisomer thereof, which is attached to the nanoparticle NP through the sulfur atom; or L is a linker of formula (III) or a stereoisomer thereof, which is attached to the nanoparticle NP through the two sulfur atoms

wherein:
X and Y independently represent a (C 2 -C 20 )hydrocarbon chain, wherein at least one carbon atom is optionally replaced by a CO group or a heteroatom selected from the group consisting of O and N; and wherein the (C 2 -C 20 )hydrocarbon chain is optionally substituted with one or more substitutents selected from the group consisting of halogen, OH, CONH 2 , CO 2 (C 1 -C 6 )alkyl and —CHO;
n and s independently represent a value from 0 to 1;
p represents a value from 1 to 2; and
A is a platinum (II) biradical selected from the group consisting of formula (IV), formula (V) and formula (VI) including any of the stereoisomers of all of them, wherein the biradical is optionally in the form of a salt, and is attached to the linker L through the single bonded oxygen atom of the carboxyl groups

with the condition that:
when in the linker of formula (II) or formula (III), n=1 or s=1; the platinum (II) biradical is attached to one molecule of linker of formula (II) or formula (III), thereby forming two COO—Pt bonds with the same linker molecule; and
when in the linker of formula (II) or formula (III), n=0 or s=0; the platinum (II) biradical is attached to two independent linker molecules of formula (II) or formula (III), thereby forming a COO—Pt bond with each of these two linker molecules; and
being at least 45% of the linkers L of formula (II) or formula (III) in the form of free carboxyl groups.

2. The conjugate according to claim 1 , having a surface electrostatic absolute charge of at least 25 mV under physiological conditions.

3. The conjugate according to claim 2 , wherein X represents —(CH 2 ) m —and Y represents —(CH 2 ) r —, wherein m represents a value from 2 to 10 with the condition that m+n represents a value from 2 to 10; and r represents a value from 2 to 10 with the condition that r+s represents a value from 2 to 10.

4. The conjugate according to claim 2 , wherein NP is a gold nanoparticle.

5. The conjugate according to claim 2 , wherein the nanoparticle is a nanosphere having a diameter from 4 to 20 nm.

6. The conjugate according to claim 2 , which has colloidal stability in a physiological medium.

7. The conjugate according to claim 2 , wherein in the linker of formula (II), n=0; and in the linker of formula (III), s=0.

8. The conjugate according to claim 3 , wherein in the linker of formula (II), n=0 and m=10; and in the linker of formula (III), p=2, s=0 and r=4.

9. The conjugate according to claim 2 , wherein A is a platinum (II) biradical of formula (IV).

10. A process for the preparation of a conjugate of formula (I) as defined in claim 1 , comprising the following steps:
a) reacting a gold, silver or platinum nanoparticle NP with an excess of a compound selected from the group consisting of formula (IIa), formula (IIIa), a stereoisomer, and a salt of any of the formulas (IIa) and (IIIa), in an aqueous solution to give rise to an intermediate conjugate

wherein X, n, p, Y and s have the same meaning as in claim 1 ; and eliminating via dialysis the non-reactive molecules of the compound of formula (IIa) or formula (IIIa) of the colloidal solution after conjugation; and
b) reacting the intermediate conjugate obtained in step a) with an excess of a platinum (II) compound to give rise to a conjugate of formula (I) having colloidal stability, in an aqueous solution in the presence of a base, the platinum (II) compound being selected from the group consisting of formula (IVa), formula (Va), formula (VIa),

and a salt of any of the formulas (IVa), (Va) and (Via), including any of the stereoisomers thereof, followed by stopping the reaction to eliminate the excess of the platinum (II) compound when at least 45% of the linkers L of formula (II) or formula (III) in the resulting conjugate are in the form of free carboxyl groups.

11. A pharmaceutical composition comprising a conjugate of formula (I) as defined in claim 1 together with one or more pharmaceutically acceptable excipients.

12. The composition according to claim 11 , which is administered by intravenous, subcutaneous or intramuscular injection.

13. A method for the treatment of cancer in a mammal, including a human, the method comprising administering to said mammal an effective amount of the conjugate of formula (I) as defined in claim 1 , together with one or more pharmaceutically acceptable excipients.

14. The method of treatment according to claim 13 , wherein the nanoparticle is a gold nanosphere having a diameter from 4 to 20 nm.

15. The method of treatment according to claim 13 , wherein in the linker of formula (II) m=10, and in the linker of or formula (III) p=2 and r=4.

16. The method of treatment according to claim 13 , wherein A is a platinum (II) biradical of formula (IV).

17. The conjugate according to claim 4 , wherein the nanoparticle is a nanosphere having a diameter from 4 to 20 nm.

18. The conjugate according to claim 17 , wherein A is a platinum (II) biradical of formula (IV).

Assignees

• Franco Puntes Victor
• Domíguez Puente Fernando
• Romero Martínez Francisco Manuel
• Gallego Rubio Óscar
• Fundacio Privada Inst Catala De Nanotecnologia
• Icrea
• Univ Santiago Compostela
• Univ Valencia
• Fundacio Inst De Recerca De L Hospital De La Santa Creu J Sant Pau

Inventors

• Franco Puntes Victor
• Domíguez Puente Fernando
• Romero Martínez Francisco Manuel
• Gallego Rubio Óscar

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title

• A61K47/6923 Primary

  the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title

• A61K47/48861 Primary

  Human Necessities · mapped topic